Tenofovir disoproxil fumarate (TDF)
Sponsors
Gilead Sciences, University of Washington, National Institute of Allergy and Infectious Diseases (NIAID), Govind Ballabh Pant Hospital, Janssen Sciences Ireland UC
Conditions
Acute on Chronic Liver FailureChronic HBV InfectionChronic Hepatitis BHIV InfectionsHIV-1 InfectionsHealthyHepatitis BHepatitis B Virus (HBV)
Early Phase 1
Phase 1
Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status
CompletedNCT01040091
Start: 2009-12-31End: 2014-04-30Updated: 2016-12-16
A Single and Multiple Ascending Dose Study of JNJ-64457744
TerminatedNCT05423106
Start: 2022-07-04End: 2023-03-20Updated: 2025-02-03
Phase 2
Phase 3
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
CompletedNCT00112047
Start: 2003-07-31End: 2009-06-30Updated: 2010-10-13
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
CompletedNCT00557245
Start: 2008-05-31End: 2013-10-31Updated: 2019-04-19
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
CompletedNCT00734162
Start: 2008-12-31End: 2015-12-31Updated: 2016-09-01
Phase 4
Unknown Phase
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
CompletedNCT01066858
Start: 2011-03-22End: 2015-11-30Updated: 2022-09-23
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
TerminatedNCT02258581
Start: 2014-12-09End: 2017-08-14Updated: 2017-10-03
Effect of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B
Not yet recruitingNCT06896630
Start: 2025-04-10End: 2026-05-01Target: 172Updated: 2025-04-04